GLP-1 Medications Before Surgery or Anesthesia: When to Hold Treatment and What Patients Need to Know

Patients taking semaglutide, tirzepatide, or another GLP-1-based medication often ask how many days they must stop treatment before surgery. Current guidance no longer supports one universal answer for every patient. Many lower-risk patients may be able to continue therapy before an elective procedure, while higher-risk patients may need additional precautions based on dose escalation, gastrointestinal symptoms, medication dose, other conditions that slow gastric emptying, and the type of procedure or anesthesia planned.

The concern is delayed gastric emptying. Food or liquid remaining in the stomach during general anesthesia or deep sedation can increase the risk of regurgitation and pulmonary aspiration. At the same time, unnecessarily withholding a medication used for diabetes or chronic weight management can create other problems. The surgeon, anesthesia team, and prescribing clinician should therefore coordinate the plan rather than relying on a fixed internet timetable.

At Optimal Health Medical in Stamford, Connecticut, Dr. Henry C. Sobo, M.D. can help established patients coordinate the medication-management side of perioperative planning while the procedural and anesthesia teams determine the final fasting and anesthesia instructions.

Related Dr. Sobo resources:
GLP-1 weight loss |
medical weight loss |
semaglutide |
tirzepatide

GLP-1 Before Surgery: At a Glance

Why GLP-1 Medications Matter Before Anesthesia

GLP-1 receptor agonists such as semaglutide can slow gastric emptying. Tirzepatide acts on both GIP and GLP-1 receptors and can also delay gastric emptying. This effect is part of the reason these medications can increase fullness and reduce food intake.

Before anesthesia, however, slower stomach emptying can create a safety concern. A patient may have residual food or liquid in the stomach even after following routine fasting instructions. During general anesthesia or deep sedation, normal airway-protective reflexes are reduced. If stomach contents move backward into the esophagus and enter the lungs, pulmonary aspiration can occur.

FDA labeling for both Wegovy and Zepbound warns about reports of pulmonary aspiration during procedures involving general anesthesia or deep sedation and instructs patients to tell healthcare providers about planned surgeries or procedures.

Do All Patients Need to Stop Their GLP-1 Medication?

No. Current multi-society guidance moved away from a universal rule requiring every patient to withhold GLP-1 therapy for the same period before elective surgery.

For many people who are on a stable dose, do not have significant gastrointestinal symptoms, and do not have another major gastric-emptying disorder, continuation of therapy may be reasonable.

Other patients may require additional precautions. The final decision depends on the patient’s aspiration risk and the consequences of interrupting treatment.

Who Is at Higher Risk for Delayed Stomach Emptying?

Risk is not determined by the medication name alone. Several patient-specific and treatment-specific factors can increase concern about retained stomach contents.

Examples of other relevant conditions may include documented gastroparesis or neurologic disorders associated with impaired gastrointestinal motility. The procedural team determines how much each factor changes the actual anesthesia risk.

Why Aspiration Is the Main Safety Concern

General anesthesia and deep sedation reduce protective airway reflexes. If significant stomach contents remain, material can regurgitate and enter the lungs. This is called pulmonary aspiration.

Aspiration can cause respiratory complications and may be serious. Preventing it is one reason patients are instructed to fast before surgery.

The challenge with GLP-1 therapy is that the number of fasting hours does not always perfectly predict whether the stomach is empty. That is why current guidance looks at symptoms, dose changes, medication dose, additional gastric-emptying conditions, and the specific procedure rather than relying on only one cutoff.

How a 24-Hour Liquid-Only Diet May Reduce Risk

For selected patients considered at higher risk, current perioperative guidance describes a liquid-only diet for 24 hours before the procedure as one possible risk-reduction strategy.

This should not be interpreted as permission to create your own fasting plan. The surgical or anesthesia team must specify what liquids are permitted and when all oral intake must stop.

This distinction is especially important for patients with diabetes. Changing food intake while also modifying diabetes medications can alter glucose levels. Insulin or other glucose-lowering medications may require separate instructions.

A 24-hour liquid plan also does not mean every patient taking a GLP-1 needs this precaution. It is one option used for selected higher-risk patients.

When Point-of-Care Gastric Ultrasound May Help

Some anesthesia teams can use point-of-care gastric ultrasound shortly before a procedure to estimate whether the stomach appears empty or contains fluid or solid material.

This may be useful when the clinical history leaves uncertainty and proceeding with the planned procedure is otherwise desirable.

Gastric ultrasound:

• is not required for every patient taking a GLP-1 medication;
• depends on trained personnel and available equipment;
• does not replace clinical judgment; and
• does not guarantee that aspiration cannot occur.

Severe gastrointestinal symptoms or other significant risk factors may alter the plan regardless of ultrasound findings.

When Might an Elective Procedure Be Delayed?

Elective procedures allow time to reduce modifiable risk. Postponement may be considered when a patient is in a high-risk portion of dose escalation, has persistent vomiting or other significant gastrointestinal symptoms, or has another factor suggesting substantial delayed gastric emptying.

The purpose is to improve patient safety, not to penalize someone for taking a GLP-1 medication.

Urgent or emergency surgery is different. Necessary care cannot always wait for an elective medication schedule. In those situations, the anesthesia team manages aspiration risk according to the clinical circumstances, which may include treating the patient as having a full stomach and using appropriate airway precautions.

What Should You Tell the Surgeon and Anesthesia Team?

Provide the complete medication information rather than simply saying, “I take a weight-loss shot.”

Tell the team:

• the exact brand and generic medication name;
• whether it is injected or taken orally;
• the current dose;
• how often it is taken;
• the date and time of the most recent dose;
• whether the dose was recently increased;
• whether the medication is being used for diabetes, weight management, or another indication;
• whether you currently have nausea, vomiting, abdominal pain, bloating, reflux, severe constipation, or unusual early fullness;
• whether you have gastroparesis or another gastrointestinal motility disorder; and
• all other prescription medications, over-the-counter products, and supplements.

Do not assume that an automatically imported medication list is current or that every clinician involved has seen the same information.

What If You Take a GLP-1 Medication for Diabetes?

Patients using a GLP-1-based medication as part of diabetes treatment have two competing concerns: aspiration risk and glucose control.

Temporarily withholding a glucose-lowering medication may contribute to higher blood glucose. Surgery itself can also raise glucose through the stress response. At the same time, fasting and changes in insulin or sulfonylurea treatment can increase the risk of low blood glucose.

A perioperative diabetes plan may therefore include:

• glucose monitoring;
• changes to insulin or other diabetes medication;
• instructions for treating hypoglycemia;
• fasting and clear-liquid instructions;
• when normal meals can resume; and
• when GLP-1 treatment should restart.

Do not compensate for a medication that has been held by independently changing insulin or another diabetes treatment.

What If the GLP-1 Medication Is Used for Weight Management?

Patients taking GLP-1 therapy for obesity or chronic weight management still need an individualized perioperative plan.

An interruption may affect appetite, gastrointestinal symptoms, and continuity of treatment. After surgery, nausea, constipation, opioid pain medication, immobility, dehydration, and dietary restrictions can overlap with the gastrointestinal effects of GLP-1 therapy.

The goal is to avoid restarting medication prematurely while the patient is unable to maintain adequate fluid or food intake, while also avoiding a longer treatment interruption than necessary.

How Should GLP-1 Treatment Be Restarted After Surgery?

There is no single restart time that applies to every medication and procedure.

The prescriber and procedural team may consider:

• the type and extent of surgery;
• the patient’s ability to eat and drink;
• return of gastrointestinal function;
• persistent nausea or vomiting;
• hydration status;
• blood glucose when relevant;
• how many doses were missed; and
• the medication’s product-specific instructions.

A patient should not automatically resume a previously tolerated high dose after a prolonged interruption without first confirming the correct restart strategy. Depending on the medication and length of the interruption, dose re-escalation may need to be considered.

A Practical Pre-Procedure Checklist for GLP-1 Patients

• Tell the surgeon and anesthesia team the exact GLP-1 or GIP/GLP-1 medication you use.
• Provide the current dose, schedule, indication, and date and time of the most recent dose.
• Report whether the dose was recently increased.
• Report nausea, vomiting, bloating, abdominal pain, severe constipation, reflux, or unusual fullness.
• Ask whether your medication should be continued or temporarily withheld.
• Ask whether a 24-hour liquid-only diet applies to your situation.
• Follow the exact fasting instructions provided for your procedure.
• If you have diabetes, obtain a specific glucose-management plan.
• Ask when and at what dose treatment should restart.
• If instructions from different clinicians conflict, ask the teams to reconcile the plan rather than choosing one yourself.

A Simple Decision Framework for Elective Procedures

The current risk-based approach can be understood as a sequence rather than a fixed number of medication-free days.

1. Determine whether the patient appears lower risk or higher risk.

A lower-risk patient may be on a stable dose, have no significant gastrointestinal symptoms, and have no other major condition that slows gastric emptying. A higher-risk patient may have recent dose escalation, persistent gastrointestinal symptoms, a higher dose with significant symptoms, or another disorder affecting gastric emptying.

2. Choose the appropriate risk-reduction strategy.

Depending on risk, the procedure may proceed under standard instructions, or the team may recommend a 24-hour liquid-only diet, changes to the anesthesia plan, gastric ultrasound, temporary medication withholding, or postponement of an elective procedure.

3. Plan the postoperative restart.

Before the procedure, patients should ideally know who will determine when the medication restarts and whether a dose adjustment could be necessary after a longer interruption.

Why FDA Labels Do Not Give One Perfect “Safe Hold Time”

Semaglutide and tirzepatide are long-acting medications, and their effects on gastric emptying do not translate neatly into one medication-free interval that guarantees the stomach will be empty.

Current FDA labeling warns patients and clinicians about pulmonary aspiration during general anesthesia or deep sedation and directs patients to notify healthcare providers about planned procedures. The labels do not establish one withholding interval proven to eliminate aspiration risk.

This is one reason individualized assessment remains important. A rigid schedule can create false reassurance if a patient continues to have marked nausea, vomiting, bloating, or another indicator of delayed emptying despite having withheld medication.

Procedures With Deep Sedation Still Require Planning

The issue is not limited to major operations requiring a breathing tube. FDA warnings also refer to procedures involving deep sedation.

Relevant procedures can therefore include:

• upper endoscopy;
• colonoscopy;
• interventional procedures;
• some outpatient surgeries;
• dental or oral procedures using deep sedation; and
• other procedures in which protective airway reflexes are reduced.

For colonoscopy, bowel preparation creates an additional layer of planning because food intake, fluid intake, diabetes treatment, and fasting instructions may all change simultaneously. Follow the gastroenterology and anesthesia instructions specific to that procedure rather than applying instructions from a different surgery.

How Dr. Sobo Can Coordinate the Medication Side of the Plan

For established patients of Optimal Health Medical, Dr. Sobo can review the medication-management portion of perioperative planning, including the current GLP-1 dose, indication, recent dose changes, gastrointestinal symptoms, treatment response, and possible consequences of an interruption.

The surgeon and anesthesia team remain responsible for determining anesthesia-specific fasting instructions, aspiration precautions, and whether a planned procedure should proceed.

The safest workflow is coordinated communication. The key question is not merely, “How many days should I hold my shot?” It is:

What is my aspiration risk, what are the consequences of withholding treatment, and what plan best fits this particular procedure and my medical situation?

GLP-1 Before Surgery Care in Stamford, Connecticut

Patients in Stamford, Greenwich, Fairfield County, and surrounding Connecticut communities who receive GLP-1 treatment through Optimal Health Medical can discuss medication management with Dr. Henry C. Sobo before a planned procedure.

Dr. Sobo can help clarify current medication dosing, recent side effects, diabetes or weight-management considerations, and the medication restart plan while coordinating with the clinicians responsible for the surgery and anesthesia.

Frequently Asked Questions About GLP-1 Before Surgery

Should I stop Ozempic before surgery?

Not automatically. Current perioperative guidance uses individualized risk assessment rather than requiring every patient to stop a GLP-1 medication for the same number of days. Your anesthesia and surgical teams should consider your dose, recent dose increases, gastrointestinal symptoms, other conditions that affect gastric emptying, procedure type, and the consequences of temporarily withholding treatment.

Should I stop Wegovy before anesthesia?

There is no universal answer for every patient. Many lower-risk patients may be able to continue Wegovy, while patients at higher risk for delayed gastric emptying may need additional precautions such as a liquid-only diet, medication withholding, gastric ultrasound, changes to the anesthesia plan, or postponement of an elective procedure. Follow your procedural team’s instructions.

Should I stop Zepbound before surgery?

The same risk-based principle applies to tirzepatide. Zepbound can delay gastric emptying, and its FDA prescribing information warns about pulmonary aspiration during general anesthesia or deep sedation. The surgeon, anesthesiologist, and prescribing clinician should coordinate the plan rather than relying on a fixed withholding schedule.

Why can GLP-1 medications affect anesthesia?

GLP-1-based medications can slow gastric emptying. If food or liquid remains in the stomach during general anesthesia or deep sedation, it can regurgitate and enter the lungs. This is pulmonary aspiration. Because standard fasting does not guarantee an empty stomach in every GLP-1 user, current guidance considers individual risk factors.

What symptoms should I report before surgery?

Report nausea, vomiting, abdominal pain, bloating, reflux, marked fullness, severe constipation, inability to tolerate food, or a recent dose increase. You should also tell the anesthesia team about gastroparesis or another condition known to delay gastric emptying. These details may change the perioperative plan.

What is a 24-hour liquid-only diet before surgery?

For selected patients at higher risk for delayed gastric emptying, current guidance may recommend a liquid-only diet during the 24 hours before a procedure. The anesthesia or procedural team must tell you exactly what liquids are permitted and when all intake must stop. Do not create your own fasting or liquid-diet schedule.

Can gastric ultrasound show whether my stomach is empty?

Point-of-care gastric ultrasound can sometimes help an experienced anesthesia clinician estimate whether significant stomach contents remain. It can be useful when there is uncertainty, but it is not required for every GLP-1 patient, is not available in every setting, and does not replace clinical judgment or guarantee that aspiration cannot occur.

What if I take a GLP-1 medication for diabetes?

Temporarily withholding a glucose-lowering medication can affect blood glucose, while surgery, fasting, insulin changes, and other diabetes medications may also change glucose control. Patients with diabetes need coordinated instructions rather than simply stopping treatment. The plan may include glucose checks, medication adjustments, and specific postoperative restart guidance.

When can I restart my GLP-1 medication after surgery?

Restart timing depends on the procedure, return of gastrointestinal function, ability to eat and drink, nausea or vomiting, hydration, glucose needs, length of the medication interruption, and the specific drug. After a prolonged gap, patients should not automatically restart a previously tolerated high dose without confirming the appropriate dose with the prescribing clinician.

Where can I discuss my GLP-1 medication plan before surgery in Connecticut?

Patients receiving care through Optimal Health Medical in Stamford can discuss semaglutide, tirzepatide, or other GLP-1 medication-management questions with Dr. Henry C. Sobo before a planned procedure. The final fasting, anesthesia, and procedural instructions should still come from the surgeon and anesthesia team responsible for the procedure.

Sources

• American Society of Anesthesiologists — New Multi-Society GLP-1 Clinical Practice Guidance
• American Society of Anesthesiologists — Drugs for Diabetes or Weight Loss: What to Know Before Surgery
• U.S. Food and Drug Administration — Wegovy Prescribing Information, 2026
• U.S. Food and Drug Administration — Zepbound Prescribing Information, 2026
• Dr. Sobo — GLP-1 Weight Loss
• Dr. Sobo — Medical Weight Loss
• Dr. Sobo — Semaglutide
• Dr. Sobo — Tirzepatide

Medically reviewed by

Dr. Henry C. Sobo, M.D.

Director of Optimal Health Medical, LLC in Stamford, Connecticut, with decades of experience in conventional, integrative, and physician-guided medical care.